GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (OTCPK:NONOF) » Definitions » Cyclically Adjusted PS Ratio

Novo Nordisk A/S (Novo Nordisk A/S) Cyclically Adjusted PS Ratio : 27.64 (As of Apr. 27, 2024)


View and export this data going back to . Start your Free Trial

What is Novo Nordisk A/S Cyclically Adjusted PS Ratio?

As of today (2024-04-27), Novo Nordisk A/S's current share price is $124.64. Novo Nordisk A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $4.51. Novo Nordisk A/S's Cyclically Adjusted PS Ratio for today is 27.64.

The historical rank and industry rank for Novo Nordisk A/S's Cyclically Adjusted PS Ratio or its related term are showing as below:

NONOF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 8.17   Med: 11.69   Max: 29.45
Current: 28.86

During the past years, Novo Nordisk A/S's highest Cyclically Adjusted PS Ratio was 29.45. The lowest was 8.17. And the median was 11.69.

NONOF's Cyclically Adjusted PS Ratio is ranked worse than
88.71% of 505 companies
in the Biotechnology industry
Industry Median: 5.24 vs NONOF: 28.86

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novo Nordisk A/S's adjusted revenue per share data for the three months ended in Dec. 2023 was $2.154. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $4.51 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novo Nordisk A/S Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Novo Nordisk A/S's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Cyclically Adjusted PS Ratio Chart

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.28 10.42 16.05 17.24 22.72

Novo Nordisk A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.24 19.19 19.08 21.53 22.72

Competitive Comparison of Novo Nordisk A/S's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Novo Nordisk A/S's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's Cyclically Adjusted PS Ratio falls into.



Novo Nordisk A/S Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Novo Nordisk A/S's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=124.64/4.51
=27.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Novo Nordisk A/S's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=2.154/116.7000*116.7000
=2.154

Current CPI (Dec. 2023) = 116.7000.

Novo Nordisk A/S Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.710 99.600 0.832
201406 0.747 99.700 0.874
201409 0.735 99.700 0.860
201412 0.782 99.400 0.918
201503 0.702 100.200 0.818
201506 0.788 100.300 0.917
201509 0.784 100.200 0.913
201512 0.827 99.800 0.967
201603 0.797 100.200 0.928
201606 0.816 100.600 0.947
201609 0.819 100.200 0.954
201612 0.833 100.300 0.969
201703 0.818 101.200 0.943
201706 0.881 101.200 1.016
201709 0.863 101.800 0.989
201712 0.904 101.300 1.041
201803 0.913 101.700 1.048
201806 0.884 102.300 1.008
201809 0.897 102.400 1.022
201812 0.942 102.100 1.077
201903 0.927 102.900 1.051
201906 0.953 102.900 1.081
201909 0.941 102.900 1.067
201912 1.020 102.900 1.157
202003 1.063 103.300 1.201
202006 0.966 103.200 1.092
202009 1.049 103.500 1.183
202012 1.130 103.400 1.275
202103 1.168 104.300 1.307
202106 1.160 105.000 1.289
202109 1.227 105.800 1.353
202112 1.270 106.600 1.390
202203 1.363 109.900 1.447
202206 1.288 113.600 1.323
202209 1.336 116.400 1.339
202212 1.514 115.900 1.524
202303 1.701 117.300 1.692
202306 1.755 116.400 1.760
202309 1.872 117.400 1.861
202312 2.154 116.700 2.154

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novo Nordisk A/S  (OTCPK:NONOF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Novo Nordisk A/S Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.